Ligand source activities (1 row/activity)
| Ligands (move mouse cursor over ligand name to see structure) | Receptor | Activity | Chemical information | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sel. page | Common name
| GPCRdb ID
| Reference ligand
| Vendors | Species
| Assay Type
| Activity Type
| Activity Relation
| Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description
| Source
| Mol weight | Rot Bonds | H don | H acc | LogP | Smiles
| DOI
| |
Ligands (move mouse cursor over ligand name to see structure)
| Receptor
| Activity
| Chemical information
| |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sel. page | Common name
| GPCRdb ID
| Reference ligand
| Vendors | Species
| Assay Type
| Activity Type
| Activity Relation
| Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description
| Source
| Mol weight | Rot Bonds | H don | H acc | LogP | Smiles
| DOI
| |
| 12455 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.7 | 6.7 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| 65080 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.7 | 6.7 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| CHEMBL4105357 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.7 | 6.7 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| 12455 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.6 | 6.6 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| 65080 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.6 | 6.6 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| CHEMBL4105357 | 3099 | None | 45 | Human | Functional | pEC50 | = | 6.6 | 6.6 | - | 1 | Activation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assayActivation of full-length human TAS2R16 expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio in presence of (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid by Fluo-4 dye based FLIPR assay |
ChEMBL | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | nan | ||
| 1499 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| 3779 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| 3779.0 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| 536 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| CHEMBL434 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| DB01064 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.3 | 8.3 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
ChEMBL | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | nan | ||
| 1499 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| 3779 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| 3779.0 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| 536 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| CHEMBL434 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| DB01064 | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.1 | 8.1 | -63 | 38 | Agonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R16 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay |
Drug Central | 211 | 4 | 4 | 4 | 1.1 | CC(NCC(c1ccc(c(c1)O)O)O)C | None | ||
| 12451 | 1314 | None | 0 | Human | Functional | pEC50 | = | 1.7 | 1.7 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 457 | 7 | 7 | 12 | -3.1 | C1=CC=C(C=C1)C(C#N)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)O)O | 12379855 | ||
| 2180 | 1314 | None | 0 | Human | Functional | pEC50 | = | 1.7 | 1.7 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 457 | 7 | 7 | 12 | -3.1 | C1=CC=C(C=C1)C(C#N)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)O)O | 12379855 | ||
| CHEMBL1967951 | 1314 | None | 0 | Human | Functional | pEC50 | = | 1.7 | 1.7 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 457 | 7 | 7 | 12 | -3.1 | C1=CC=C(C=C1)C(C#N)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)O)O | 12379855 | ||
| 12452 | 615 | None | 0 | Human | Functional | pEC50 | = | 2.4 | 2.4 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 342 | 4 | 8 | 11 | -5.4 | C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O | 20965151 | ||
| 441422 | 615 | None | 0 | Human | Functional | pEC50 | = | 2.4 | 2.4 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 342 | 4 | 8 | 11 | -5.4 | C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O | 20965151 | ||
| CHEMBL1360334 | 615 | None | 0 | Human | Functional | pEC50 | = | 2.4 | 2.4 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 342 | 4 | 8 | 11 | -5.4 | C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O | 20965151 | ||
| 12454 | 3462 | None | 0 | Human | Functional | pEC50 | = | 2.9 | 2.9 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 286 | 4 | 5 | 7 | -1.6 | C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | 12379855 | ||
| 439503 | 3462 | None | 0 | Human | Functional | pEC50 | = | 2.9 | 2.9 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 286 | 4 | 5 | 7 | -1.6 | C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | 12379855 | ||
| 12455 | 3099 | None | 45 | Human | Functional | pEC50 | = | 3.0 | 3.0 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | 12379855 | ||
| 65080 | 3099 | None | 45 | Human | Functional | pEC50 | = | 3.0 | 3.0 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | 12379855 | ||
| CHEMBL4105357 | 3099 | None | 45 | Human | Functional | pEC50 | = | 3.0 | 3.0 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 256 | 3 | 4 | 6 | -1.1 | C1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O | 12379855 | ||
| 12453 | 123 | None | 0 | Human | Functional | pEC50 | = | 3.2 | 3.2 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 301 | 4 | 4 | 8 | -1.2 | OC[C@H]1O[C@@H](OC2=CC=C(C=C2)[N+]([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O | 28798468 | ||
| 161880 | 123 | None | 0 | Human | Functional | pEC50 | = | 3.2 | 3.2 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 301 | 4 | 4 | 8 | -1.2 | OC[C@H]1O[C@@H](OC2=CC=C(C=C2)[N+]([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O | 28798468 | ||
| CHEMBL4462691 | 123 | None | 0 | Human | Functional | pEC50 | = | 3.2 | 3.2 | - | 1 | UnclassifiedUnclassified |
Guide to Pharmacology | 301 | 4 | 4 | 8 | -1.2 | OC[C@H]1O[C@@H](OC2=CC=C(C=C2)[N+]([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O | 28798468 | ||
| 2268 | 3170 | None | 0 | Human | Functional | pIC50 | = | 3.5 | 3.5 | -1 | 2 | UnclassifiedUnclassified |
Guide to Pharmacology | 285 | 7 | 1 | 3 | 2.2 | CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC | 21629661 | ||
| 4357 | 3170 | None | 0 | Human | Functional | pIC50 | = | 3.5 | 3.5 | -1 | 2 | UnclassifiedUnclassified |
Guide to Pharmacology | 285 | 7 | 1 | 3 | 2.2 | CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC | 21629661 | ||
| 4911 | 3170 | None | 0 | Human | Functional | pIC50 | = | 3.5 | 3.5 | -1 | 2 | UnclassifiedUnclassified |
Guide to Pharmacology | 285 | 7 | 1 | 3 | 2.2 | CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC | 21629661 | ||
| CHEMBL897 | 3170 | None | 0 | Human | Functional | pIC50 | = | 3.5 | 3.5 | -1 | 2 | UnclassifiedUnclassified |
Guide to Pharmacology | 285 | 7 | 1 | 3 | 2.2 | CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC | 21629661 | ||
| DB01032 | 3170 | None | 0 | Human | Functional | pIC50 | = | 3.5 | 3.5 | -1 | 2 | UnclassifiedUnclassified |
Guide to Pharmacology | 285 | 7 | 1 | 3 | 2.2 | CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC | 21629661 | ||
Showing 1 to 37 of 37 entries
| Ligands (move mouse cursor over ligand name to see structure) | Receptor | Activity | Chemical information | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sel. page | Common name
| GPCRdb ID
| Reference ligand
| Vendors | Species
| Assay Type
| Activity Type
| Activity Relation
| Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description
| Source
| Mol weight | Rot Bonds | H don | H acc | LogP | Smiles
| DOI
| |
Ligands (move mouse cursor over ligand name to see structure)
| Receptor
| Activity
| Chemical information
| |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sel. page | Common name
| GPCRdb ID
| Reference ligand
| Vendors | Species
| Assay Type
| Activity Type
| Activity Relation
| Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description
| Source
| Mol weight | Rot Bonds | H don | H acc | LogP | Smiles
| DOI
| |
| No data available in table | ||||||||||||||||||||||
Showing 0 to 0 of 0 entries